Patents Examined by Magdalene K. Sgagias
  • Patent number: 11401316
    Abstract: The present invention pertains to novel high avidity antigen recognizing constructs against Human Papilloma Virus antigens. The invention provides novel T cell receptor (TCR) based molecules which are selective and specific for HPV 16/18 proteins E5, E6 and E7. The TCR of the invention, and HPV antigen-binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of HPV infection, as well as for the diagnosis, treatment and prevention of HPV infection mediated secondary diseases as HPV infection caused cancers, such as cervical, nasopharyngeal or head and neck cancer. Further provided are nucleic acids encoding the proteins of the invention, and recombinant cells expressing the same.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: August 2, 2022
    Assignee: MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT
    Inventors: Thomas Blankenstein, Gerald Willimsky
  • Patent number: 11390851
    Abstract: The present invention provides a method for generation, isolation, detection and/or analysis of cardiomyocytes derived from a starting cell composition comprising pluripotent and/or multipotent stem cells, the method comprising the steps a) differentiating said pluripotent and/or multipotent stem cells into cardiovascular cells, thereby generating a sample comprising cardiomyocytes and non-cardiomyocytes; and b) labeling the non-cardiomyocytes of said sample with more than one antibody or antigen binding fragment thereof specific for antigens of non-cardiomyocytes and c) depleting said labeled non-cardiomyocytes from said sample; and optionally d) labeling the cardiomyocytes of said sample with at least one antibody or antigen binding fragment thereof specific for antigen(s) of cardiomyocytes; and e) enriching said labeled cardiomyocytes and detecting and isolating cardiomyocyte subtypes derived from said pluripotent and/or multipotent stem cells.
    Type: Grant
    Filed: May 30, 2017
    Date of Patent: July 19, 2022
    Assignee: Miltenyi Biotec B.V. & Co. KG
    Inventors: Kristin Becker, Dominik Eckardt, Andreas Bosio
  • Patent number: 11359180
    Abstract: Provided is a method for producing myocardial cells from pluripotent stem cells. The myocardial cell production method provided by the present invention includes supplying an artificially produced synthetic peptide to a cell culture that contains pluripotent stem cells. The synthetic peptide is a peptide that contains a myocardial cell differentiation-inducing peptide sequence that induces pluripotent stem cells into myocardial cells. The myocardial cell differentiation-inducing peptide sequence is an amino acid sequence selected from the group consisting of (i) an amino acid sequence constituting the signal peptide of any protein belonging to the amyloid precursor protein (APP) family, (ii) a partial amino acid sequence of the amino acid sequence according to (i), and (iii) a modified amino acid sequence from the amino acid sequence according to (i) or (ii).
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: June 14, 2022
    Assignees: Toagosei Co., Ltd., Kyoto University
    Inventors: Tetsuhiko Yoshida, Kenichi Tanaka, Nahoko Baileykobayashi, Yoshinori Yoshida
  • Patent number: 11345734
    Abstract: The present invention relates to a cell which comprises a chimeric antigen receptor (CAR) and a signal transduction modifying protein, selected from one of the following: (i) a truncated protein which comprises an SH2 domain from a protein which binds a phosphorylated immunoreceptor tyrosine-based activation motif (ITAM), but lacks a kinase domain; (ii) a truncated protein which comprises an SH2 domain from a protein which binds a phosphorylated immunoreceptor tyrosine-based inhibition motif (ITIM) but lacks a phosphatase domain; (iii) a fusion protein which comprises (a) an SH2 domain from a protein which binds a phosphorylated immunoreceptor tyrosine-based activation motif (ITAM) or from a protein which binds a phosphorylated immunoreceptor tyrosine-based inhibition motif (ITIM); and (ii) a heterologous domain.
    Type: Grant
    Filed: May 31, 2016
    Date of Patent: May 31, 2022
    Assignee: AUTOLUS LIMITED
    Inventors: Martin Pulé, Shaun Cordoba, Simon Thomas, Khai Kong
  • Patent number: 11326185
    Abstract: The present invention relates to stable and high-producing site-specific integration (SSI) host cells, e. g. Chinese hamster ovary (CHO)-derived host cells, methods to produce and to use them.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: May 10, 2022
    Assignees: LONZA BIOLOGICS PLC, PFIZER INC.
    Inventors: James Rance, Robert Young, Michael J. Agostino, Mark Moffat, Lin Zhang, Baohong Zhang
  • Patent number: 11319354
    Abstract: Provided is a polynucleotide, including a cis-regulatory element and a nucleotide sequence encoding a vestigial like 4 protein, wherein the cis-regulatory element includes an uncoupling protein 1 enhancer and an uncoupling protein 1 promoter. Also provided is a viral vector including said polynucleotide. Also provided is a method of transfecting a cell or a subject with said polynucleotide or said viral vector.
    Type: Grant
    Filed: July 10, 2020
    Date of Patent: May 3, 2022
    Assignee: MASONIC MEDICAL RESEARCH LABORATORY
    Inventor: Zhiqiang Lin
  • Patent number: 11279949
    Abstract: This disclosure provides modified recombinant retroviruses comprisings containing a 2A-peptide or peptide-like coding sequence operably linked to a heterologous polynucleotide. The disclosure further relates to cells and vector expressing or comprising such vectors and methods of using such modified vectors in the treatment of disease and disorders.
    Type: Grant
    Filed: September 1, 2016
    Date of Patent: March 22, 2022
    Assignee: DENOVO BIOPHARMA LLC
    Inventors: Douglas J. Jolly, Amy H. Lin, Andrew Hofacre, Daniel J. Hogan, Derek G. Ostertag
  • Patent number: 11268158
    Abstract: The invention is directed to methods of assessing the safety of therapeutic compounds and therapeutic genetic manipulations, including integrating gene therapy vectors and genome editing. In particular, the invention provides a method, wherein the oncogenic potential of therapeutic compounds and therapeutic genetic manipulations, including integrating gene therapy vectors and genome editing, is determined by determining the percentage of differentiation blocked hematopoietic progenitor cells.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: March 8, 2022
    Assignee: ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC.
    Inventors: Brian P. Sorrentino, Sheng Zhou
  • Patent number: 11266129
    Abstract: A transgenic mouse comprising T30A, S32P, Q33L, N39D, and M470Q mutations in GPIIIa, as well as methods for making the transgenic mouse and methods for using the transgenic mouse to screen test compounds are described.
    Type: Grant
    Filed: November 5, 2019
    Date of Patent: March 8, 2022
    Inventors: Peter J. Newman, Huiying Zhi
  • Patent number: 11268107
    Abstract: Described herein are vectors, such as adeno-associated virus (AAV) vectors, and recombinant AAV expressing Smad7. The disclosed AAV vectors and rAAV can be used for therapeutic applications in the treatment and amelioration of muscle wasting, cardiac and/or skeletal muscle wasting associated with cancer cachexia.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: March 8, 2022
    Assignees: Washington State University, Baker Heart and Diabetes Institute
    Inventors: Buel Dantese Rodgers, Paul Gregorevic
  • Patent number: 11261426
    Abstract: Objects of the present invention are to provide a method for directly obtaining pluripotent stem cells which do not have tumorigenic property from body tissue and the thus obtained pluripotent stem cells. The present invention relates to SSEA-3 (+) pluripotent stem cells that can be isolated from body tissue.
    Type: Grant
    Filed: June 22, 2016
    Date of Patent: March 1, 2022
    Inventors: Mari Dezawa, Yoshinori Fujiyoshi, Youichi Nabeshima
  • Patent number: 11242508
    Abstract: The technology described herein relates to methods, assays, and compositions relating to causing a cell to assume a more pluripotent state, e.g. without introducing foreign genetic material.
    Type: Grant
    Filed: September 19, 2016
    Date of Patent: February 8, 2022
    Assignee: VCELL THERAPEUTICS, INC.
    Inventors: Charles A. Vacanti, Koji Kojima
  • Patent number: 11236402
    Abstract: The present disclosure provides adeno-associated virus (AAV) virions with altered capsid protein, where the AAV virions exhibit greater infectivity of retinal cells, when administered via intravitreal injection, compared to wild-type AAV. The present disclosure further provides methods of delivering a gene product to a retinal cell in an individual, and methods of treating ocular disease.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: February 1, 2022
    Assignee: The Regents of the University of California
    Inventors: David V. Schaffer, Ryan R. Klimczak, James T. Koerber, John G. Flannery, Deniz Dalkara Mourot, Meike Visel, Leah C. T. Byrne
  • Patent number: 11225642
    Abstract: The present invention provides: a method for producing renal progenitor cells from intermediate mesoderm cells, which comprises a step of culturing intermediate mesoderm cells in a medium containing a TGF? signaling activator(s) and a BMP inhibitor(s); the renal progenitor cells produced by the method; a pharmaceutical composition comprising the renal progenitor cells; and a therapeutic drug for kidney diseases comprising the renal progenitor cells.
    Type: Grant
    Filed: June 11, 2014
    Date of Patent: January 18, 2022
    Assignees: Kyoto University, Astellas Pharma Inc.
    Inventors: Kenji Osafune, Takafumi Toyohara, Yukiko Yamagishi
  • Patent number: 11219667
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating peripheral vascular disease, the composition comprising, as an active ingredient: (a) hepatocyte growth factor (HGF) or an isoform thereof, and stromal cell derived factor 1? (SDF-1?); or (b) a polynucleotide encoding the HGF and a polynucleotide encoding the SDF-1?. The peripheral vascular disease (for example, ischemic limb disease) can be more effectively prevented or treated through the significant promotion of vascular endothelial cell migration and angiogenesis in the case of singly using the composition of the present invention than in the case of using HGF, an isoform thereof, SDF-1? or a polynucleotide codes a protein thereof.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: January 11, 2022
    Assignee: Helixmith Co., Ltd.
    Inventors: Jae-Gyun Jeong, Jung Hun Lee, Nayeon Lee
  • Patent number: 11220671
    Abstract: Disclosed herein are methods of using a cell-derived extracellular matrix derived in-vitro from cells isolated from amniotic fluid (AFC-ECM) for the maturation of immature cardiomyocytes derived from human induced pluripotent stem cells (immature hiPSC-CMs) in culture forming mature cardiomyocytes. Also disclosed herein is a cell construct comprising a monolayer of these mature cardiomyocytes on an AFC-ECM useful for cardiotoxicity and/or proarrhythmic screening assays of drug compounds. Also disclosed herein are methods for determining the cardiotoxicity and/or proarrhythmic effect of a drug compound in vitro using such cell constructs.
    Type: Grant
    Filed: February 21, 2020
    Date of Patent: January 11, 2022
    Assignee: STEMBIOSYS, INC.
    Inventors: Travis Block, Edward S. Griffey, Todd Herron
  • Patent number: 11219696
    Abstract: The present invention relates to Adeno-associated virus 9 methods and materials useful for systemically delivering polynucleotides across the blood brain barrier. Accordingly, the present invention also relates to methods and materials useful for systemically delivering polynucleotides to the central and peripheral nervous systems. The present invention also relates to Adeno-associated virus type 9 methods and materials useful for intrathecal delivery of polynucleotides. Use of the methods and materials is indicated, for example, for treatment of lower motor neuron diseases such as spinal muscle atrophy and amyotrophic lateral sclerosis as well as Pompe disease and lysosomal storage disorders. Use of the methods and materials is also indicated, for example, for treatment of Rett syndrome.
    Type: Grant
    Filed: May 20, 2015
    Date of Patent: January 11, 2022
    Assignee: NATIONWIDE CHILDREN'S HOSPITAL
    Inventors: Brian K. Kaspar, Kevin Foust
  • Patent number: 11149277
    Abstract: A method of producing induced exosomes, the method comprising: contacting an isolated population of stem cells with an amount of a prostaglandin E receptor 4 (EP4) antagonist effective for inducing release of exosomes, whereby induced exosomes are released from the stem cells, and isolating the induced exosomes.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: October 19, 2021
    Assignee: National Health Research Institutes
    Inventor: Hua-Jung Li
  • Patent number: 11141470
    Abstract: This document provides methods and materials involved in reducing cardiac xenograft rejection. For example, methods and materials for preparing transgenic pigs expressing reduced or no endogenous Sda or SDa-like glycans derived from the porcine ?1,4 N-acetyl-galactosaminyl transferase 2 (B4GALNT2) glycosyltransferase and/or reduced or no endogenous ?-Gal antigens, methods and materials for modifying the xenograft recipient's immunological response to non-Gal antigens (e.g. CD46, CD59, CD9, PROCR, and ANXA2) to reduce cardiac xenograft rejection, and methods and materials for monitoring the progress of xenotransplant immunologic rejection are provided.
    Type: Grant
    Filed: April 24, 2017
    Date of Patent: October 12, 2021
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Christopher G. A. McGregor, Guerard W. Byrne
  • Patent number: 11103597
    Abstract: The present invention relates to nucleic acid molecules containing spacers that can be packaged into viral particles and methods of producing them. In a first aspect, the invention features a nucleic acid molecule including a first spacer (SSI); a first inverted terminal repeat (ITR1); a cloning site (CS); a second inverted terminal repeat (ITR2); and a second spacer (SS2), such as a eukaryotic spacer; operably linked to each other in a 5?-to-3? direction as: SS1-ITR1-CS-ITR2-SS2. In an embodiment, the invention features a vector comprising any of the above-described nucleic acid molecules. In another aspect, the invention features a plurality of viral particles including the nucleic acid molecule. The invention further includes a host cell including any of the above-described vectors.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: August 31, 2021
    Assignee: St. Jude Children's Research Hospital, Inc.
    Inventor: John T. Gray